NextCure (NXTC) Competitors

Hookipa Pharma (NASDAQ:HOOK) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, community ranking, risk and earnings.

Does the MarketBeat Community prefer HOOK or NXTC?

Hookipa Pharma received 9 more outperform votes than NextCure when rated by MarketBeat users. Likewise, 70.08% of users gave Hookipa Pharma an outperform vote while only 64.52% of users gave NextCure an outperform vote.

Company	Underperform	Outperform
Hookipa Pharma	Outperform Votes 89 70.08%	Underperform Votes 38 29.92%
NextCure	Outperform Votes 80 64.52%	Underperform Votes 44 35.48%

Which has more risk and volatility, HOOK or NXTC?

Hookipa Pharma has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, NextCure has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500.

Do institutionals & insiders hold more shares of HOOK or NXTC?

63.9% of Hookipa Pharma shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 3.3% of Hookipa Pharma shares are held by company insiders. Comparatively, 13.3% of NextCure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Is HOOK or NXTC more profitable?

NextCure has a net margin of 0.00% compared to Hookipa Pharma's net margin of -93.16%. Hookipa Pharma's return on equity of -36.81% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hookipa Pharma	-93.16%	-36.81%	-23.18%
NextCure	N/A	-62.50%	-53.67%

Which has higher earnings & valuation, HOOK or NXTC?

NextCure has lower revenue, but higher earnings than Hookipa Pharma. Hookipa Pharma is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hookipa Pharma	$20.13M	2.05	-$81.58M	-$4.32	-0.79
NextCure	N/A	N/A	-$62.72M	-$2.09	-0.67

Do analysts rate HOOK or NXTC?

Hookipa Pharma presently has a consensus target price of $44.67, indicating a potential upside of 1,206.04%. NextCure has a consensus target price of $4.00, indicating a potential upside of 183.69%. Given Hookipa Pharma's higher possible upside, equities analysts clearly believe Hookipa Pharma is more favorable than NextCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hookipa Pharma	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
NextCure	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media prefer HOOK or NXTC?

In the previous week, NextCure had 1 more articles in the media than Hookipa Pharma. MarketBeat recorded 7 mentions for NextCure and 6 mentions for Hookipa Pharma. Hookipa Pharma's average media sentiment score of 0.15 beat NextCure's score of -0.17 indicating that Hookipa Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hookipa Pharma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NextCure	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Hookipa Pharma beats NextCure on 10 of the 16 factors compared between the two stocks.